Medical Science Liaison
About the job
- Be a pharmacist, registered nurse, or equivalent with significant experience in all aspects of clinical trials and professional knowledge and skills working with oncology therapeutics.
- Have 4–8 years or longer of relevant pharmaceutical or related industry experience in hemato-oncology, with a proven track record of contributing to commercial, medical, and/or clinical development strategies.
- Have solid peer relationships with and exposure to external scientific and clinical experts and Key Opinion Leaders, and demonstrate the ability to proactively engage internal and external leaders and serve as a medical expert for the oncology or hematology disease area.
- Understand commercial and scientific needs on a local and global basis.
- Be intimately familiar with applicable rules and regulations and actions of relevant regulatory bodies within the assigned country or region.
- Demonstrate the ability to translate and appropriately align commercial and scientific goals and objectives and interact productively with both commercial and scientific colleagues.
- Meet the highest ethical standards in corporate medical governance.
- Have experience delivering compelling and persuasive communications on complex and controversial topics to corporate management and scientific audiences.
- Have a successful track record of initiating and leading cross-business and cross-functional planning, collaboration, and solution building.
- Have strong interpersonal skills for successful interaction with peers across the organization to achieve corporate goals.
- Have excellent written and oral communication skills.
- Be proficient in Microsoft Office, including Excel, Word, PowerPoint, and Outlook.
- Be proficient in collaboration tools, including Microsoft Teams, SharePoint, and Zoom.
- Be able to learn new technology and applications quickly.
- Be able to travel.
- Execute the Field Engagement Plan and support business objectives through advisory board meetings, national and regional educational meetings, scientific conferences, and Key Opinion Leader development programs, ensuring successful implementation.
- Implement the scientific communication strategy, including key publications from company trials and key messages in the therapeutic area and company brands, to support business strategies and life-cycle management.
- Assist with execution of the Medical Affairs plan by developing an integrated Key Opinion Leader list, ensuring sufficient coverage through field visits, educational meetings, and scientific projects, conducting speaker training, and tracking these activities.
- Work with Key Opinion Leaders in the relevant field to understand current clinical practice, challenges, and unmet needs, and share insights with the wider organization to inform and guide strategy.
- Participate in cross-functional meetings and share external customer insights with internal stakeholders.
- Work with cross-functional team members to establish and maintain relationships with Key Opinion Leaders and promote the company's reputation, dedication to patients, and expertise.
- Serve as a liaison for submission and review of Investigator-Initiated Trial proposals.
- Support healthcare-provider-related requests and programs for pre-approved products, including Named Patient Programs and Early Access Programs.
- Liaise with the Local Safety Officer and support local Risk Management Plan activities with the medical advisor.
- Support the Global Clinical Operations team in assessing trials, identifying trial sites and new investigators, managing trials, and ensuring timely delivery of the clinical trial program in Korea.
- Ensure compliance with country directives and conduct all Medical Affairs activities with integrity.
- Experience in solid tumor indications, such as lung, gastric, liver, or esophageal cancer, or hematology indications, such as lymphoma or myeloma, is preferred.
- Recognized expertise in the therapy area through clinical and/or research experience, including publications, is desired; specialty training and/or clinical experience in hemato-oncology is highly preferred.
About the company
BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Dongcheng District, China
Founded
2010
Get referred to BeOne
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
- August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
- Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.
What critics are saying
- BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
- Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
- AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.
What makes BeOne unique
- BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
- BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
- Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
Wellness Program
Paid Vacation
Growth & Insights and Company News
6 month growth
8%1 year growth
-6%2 year growth
-1%Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.
BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.
Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.
BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.
John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.